P3781
APX005M, Doxorubicin, Olaratumab in Advanced SarcomaA Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal TumorsA Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue SarcomaA Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue SarcomaA Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue SarcomaA Study of Durvalumab in Combination With Doxorubicin and Olaratumab for Advanced Soft Tissue SarcomaOlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma PatientsTrabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent LeiomyosarcomaStudy of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid TumorsA Study of Olaratumab in Soft Tissue SarcomaA Study of Olaratumab (IMC-3G3) in Prostate CancerA Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma MultiformeA Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian CancerA Study of Olaratumab in Japanese Participants With Advanced CancerA Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue SarcomaA Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With CancerA Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue SarcomaOlaratumab (LY3012207) Patient Access for Soft Tissue SarcomaOlaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma PatientsA Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic CancerA Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
P4844
Q62040144-0DA00A6C-E56C-478C-A0CF-4E392EDE11FCQ63338119-1DD07C58-1ADD-4DA3-9121-170EE5C1B465Q63575500-86B11AA5-91C5-4F3C-9A66-8B6E47057351Q63576373-647D81C9-72B0-421B-89EF-9F1A19DEEBD1Q63576701-53AF10C1-412A-41F0-B626-8349D1130CE1Q63591409-35C383CE-82C4-4513-91AD-59360537EF16Q63597755-94BCA96A-03FA-45F2-9FA7-8BCA6DC8E53EQ63613226-9A1DBAB2-60E7-49D4-AAEE-72F9D0016A52Q64653432-B06C82FD-FF93-467F-9B85-7ABD01EB48E2Q64653816-91C40F9E-1BE5-42A4-8A2A-CFF0D9038991Q64654667-51FF2182-E97A-4316-9595-75656C9381DBQ64677120-27323274-0EE0-4080-BC41-02C954FD428BQ64677428-955BF151-5BF5-4DCE-92DB-8E098EEB3F01Q64677811-BBD9F281-FAE2-4002-9905-68F64F78B9C6Q65346783-470957FB-5F2D-4930-A561-92CB27920DE3Q65348302-B0AF2C95-AFBE-47C0-9536-1438DD151576Q65401467-25AC5814-E87E-4E4B-B20F-1078F5E7BEE4Q65466148-9F6B0D2F-057A-47B0-9017-453753E3C876Q66063510-6DF6312E-B30C-4230-9F9C-E7BB1C5DD4D0Q66064828-2DCECF2F-F1E6-4BD2-B2E9-F4C774F90B91Q66072163-A5C11D0A-FCA8-4A5C-A356-3B12D0C8E7EDQ66403269-8B313877-93E8-4BA6-A2DC-E43EBAA7F6AD
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Olaratumab
@de
Olaratumab
@en
Olaratumab
@fr
أولاراتوماب
@ar
اولاراتوماب
@fa
type
label
Olaratumab
@de
Olaratumab
@en
Olaratumab
@fr
أولاراتوماب
@ar
اولاراتوماب
@fa
altLabel
IMC-3G3
@en
LY-3012207
@en
Lartruvo
@de
Lartruvo
@en
prefLabel
Olaratumab
@de
Olaratumab
@en
Olaratumab
@fr
أولاراتوماب
@ar
اولاراتوماب
@fa
P31
P486
P6366
P665
P1909
P2175
P2275
olaratumab
@en
P231
1024603-93-7
P267
P274
C₆₅₅₄H₁₀₀₇₆N₁₇₃₆O₂₀₄₈S₄₀
P2840
P2868
P3780
P486
C000589393
P6366
2778302757
P652
TT6HN20MVF
P665
P7830
Olaratumab